Implementation of the Mental Capacity Act: a national observational study of changes in place of death for older heart failure patients with or without comorbid dementia

James M. Beattie  
King's College London

Irene J. Higginson  
King's College London

Theresa A. McDonagh  
King's College London

Wei Gao  
King's College London  
wei.gao@kcl.ac.uk  
https://orcid.org/0000-0001-8298-3415

Research Article

Keywords: Heart failure, Dementia, Place of death, Mental Capacity Act, Comorbidity

DOI: https://doi.org/10.21203/rs.3.rs-636124/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Heart failure is increasingly prevalent in the growing elderly population and commonly associated with cognitive impairment. This study compared trends in place of death (PoD) of heart failure patients with / without comorbid dementia over the period of implementation of the Mental Capacity Act (MCA) in October 2007, this legislation supporting patient-centred decision making for those with reduced agency.

Methods: Analyses of death certification data for England between January 2001 and December 2018, describing the PoD and sociodemographic characteristics of all people ≥ 65 years registered with heart failure as the underlying cause of death, with / without a mention of comorbid dementia. Multiple Poisson regression modelling was used to determine the prevalence ratio (PR) of dying at home or in care homes compared to dying in hospital. Covariates included year of death, age, gender, marital status, comorbidity burden, index of multiple deprivation and urban / rural settings.

Results: 120,068 heart failure-related death records were included of which 8199 mentioned dementia as a contributory cause. The overall prevalence of dementia was 6.8%, the trend significantly increasing from 5.6% to 8.0% pre- and post-MCA (p<0.0001). Dementia was coded as unspecified (78.2%), Alzheimer's disease (13.5%) and vascular (8.3%). Those with dementia were more commonly older, female, widowed, and had more comorbidities. Pre-MCA, PoD for heart failure patients without dementia was hospital 68.2%, care homes 20.2%, 10.7% dying at home. The corresponding figures for those with comorbid dementia were 47.6%, 48.0% and 4.2%, respectively. Following MCA enforcement, PoD for those without dementia shifted from hospital to home, PR: 1.026 [95%CI: 1.024-1.029]. This trend was not significant for those with dementia, PR: 1.001 [0.988-1.015], hospital deaths increasing. Care home deaths reduced for all, with or without dementia, PR: 0.959 [0.949-0.969], and PR: 0.996 [0.993-0.998], respectively. Hospice as PoD was rare for both groups (≤0.5%) with no appreciable change over the study period.

Conclusions: Our analyses suggest the MCA did not materially affect the PoD of heart failure decedents with comorbid dementia, likely reflecting difficulties implementing this legislation in real-life clinical practice.

Background

The incidence and prevalence of heart failure varies across the world reflecting regional differences in cardiovascular disease burden, ethnic and socioeconomic diversity. While the age-adjusted incidence and prevalence of heart failure may be declining in Westernised cultures, absolute rates of these indices are increasing in parallel with societal ageing [1]. In the United Kingdom (UK), about 900,000 people are living with heart failure. The prevalence is 1–2% in the general population, rising to at least 10% in those ≥ 70 years of age. [2, 3]. The lifetime risk of developing heart failure is about 20% at 40 years, but for each age decile between 65 and 85 years, the incidence doubles for men and trebles for women [4].

Crafted by international consensus [5], a universal definition of heart failure has recently emerged as

‘…a clinical syndrome with symptoms and / or signs caused by a structural and / or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and / or objective evidence of pulmonary or systemic congestion’.

Increasingly accurate diagnostic protocols have been established, and based on the left ventricular ejection fraction (EF), the percentage volume of the diastolic blood pool ejected during systole, an updated classification system linked to the above definition has characterised four clinical phenotypes: heart failure with a reduced EF (< 40%) (HFrEF); heart failure with a mildly reduced EF [40%-49%] (HFrEF); heart failure with a preserved EF [≥ 50%] (HFrEF); and heart failure with an improved EF [baseline EF ≤ 40%, a ≥ 10% point increase from baseline EF, the improved EF > 40%] (HFimpEF) [5]. Advances in heart failure therapy, particularly those for HFpEF, have enabled some patients to live longer, more comfortable lives, but for many, heart failure remains a life limiting condition, the 5- and 10-year case-fatality rates being about 50% and 75% respectively, similar to outcomes for common cancers [3, 6]. As well as being encumbered with an unpredictable disease trajectory, this burgeoning and increasingly elderly clinical cohort usually exhibit several comorbidities which add to the complexity, and challenge the coordination required of their care [2].

Cognitive impairment, ranging from mild forms to severe as manifest in dementia, is relatively common, affecting between 25% and 70% of those with heart failure across a series of studies, and estimated at 40% overall in a recent meta-analysis [7, 8, 9]. Disordered cognition is heterogeneous and demonstrable across a range of higher cortical domains including attention, memory, speech and language processing, learning and executive function [10], such deficits beyond those arising from normative ageing of the brain. Cognitive impairment may be transitory, sometimes encountered as delirium in patients presenting with acute heart failure [11], but often occurs as a long-term progressive condition, more frequently encountered in older people with chronic heart failure compared to their age-matched healthy counterparts [12]. The impact of these persistent features tends to fluctuate over time, but even when mild, may impact heart failure patients’ self-care behaviours and treatment adherence resulting in greater rates of hospital admission and mortality [13, 14]. There appears to be no direct correlation between the severity of these two conditions [15], but dilemmas may arise when treating cognitively impaired heart failure patients, sometimes relating to the continued efficacy of established treatment modalities, ceilings of care, and resuscitation issues [16]. These confront not only professional healthcare providers but also their informal carers, usually family members, who take responsibility for much day-to-day practical support. In assisting those affected by dementia-related loss of intellectual capacity, such carers may be called upon to act as decisional proxies and offer insight into patients previously voiced values and preferences for treatment.

The Mental Capacity Act (MCA) of 2005, applicable to residents in England and Wales aged ≥ 16 years, sets out a statutory framework to foster person-centred decision making and advance care planning for those who may lack capacity due to a lifelong learning disability, or as a consequence of the transient or permanent effects of acute or long-term illnesses [17]. For people with cognitive impairment and a progressive, ultimately fatal condition
such as heart failure, the MCA may be particularly important in fulfilling goals of care close to the end of life. Achieving care in appropriate settings and the preferred place of death (PoD) are generally accepted as benchmarks of good quality end-of-life care, death at home or customary place of residence usually regarded as the desired option [18]. Given the relatively frequent association of cognitive impairment with heart failure, it might be expected that the decision-making processes legally constituted within the MCA would drive changes in the final place of care and death during the terminal phase of this condition. The code of practice setting out the standards required to comply with the MCA came fully into force on October 1st, 2007 [19]. Thus, we undertook a comparative trend analysis covering the period of implementation of this legislation to discern any resultant variation in the PoD of heart failure decedents rendered vulnerable by comorbid dementia.

**Methods**

**Study design**

This was a national population-based cross-sectional study examining anonymised death registration data collated by the Office for National Statistics (ONS) from 2001 to 2018 relating to heart failure patients resident in England.

**Data Source And Study Cohort**

In the UK the death certificate is completed by the responsible clinician, civil registration of the cause of death by a relative or another qualified informant being legally required within 5 days of medical certification. Sometimes a coroner assumes this role after a post-mortem examination or inquest. Following transcription of the information on the death certificate by the recording registrar, this is digitised and uploaded to the ONS for subsequent diagnostic coding in accordance with the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10).

This study dataset comprised all deaths registered in England from January 2001 through December 2018 of people aged ≥ 65 years for whom heart failure was recorded as the underlying cause of death. We elected to study those aged ≥ 65 years at death *a priori*, perceiving this subset to include the vast majority of heart failure decedents with or without dementia as a marker of cognitive impairment. Heart failure as the primary cause of death was determined by the allocation of any ICD-10: I50 code by the ONS. Designation of diminished intellectual capacity for this cohort was determined when dementia of any aetiology was mentioned as a contributory cause of death. The presence of comorbid dementia was indicated by the application of ICD-10 codes G30 [Alzheimer's disease]; F00 [dementia in Alzheimer's disease with late onset, atypical or mixed type, and unspecified]; F01 [vascular dementia]; F02 [dementia in other diseases classified elsewhere], or F03 [unspecified dementia]. ONS death data acquisition and coding processes are subject to regular quality assurance. Pertinent to this study period, it should be noted that in 2011 there was a change in ONS mortality data coding practice, the previous coding of unspecified cerebrovascular disease when registered as a contributory cause of death being reclassified as vascular dementia [20].

**Variables**

The outcome variable PoD and the deceased's usual place of residence are both recorded on death certificates and also codified by the ONS. Characterisation of PoD for this study was based on the classification system defined by the National End of Life Care Intelligence Network, part of Public Health England [21]. This specifies 5 groupings of PoD: (a) Hospital, which incorporates all acute, specialist, and community hospitals whether they be National Health Service (NHS) or private, but not psychiatric hospitals; (b) Care home, including residential and nursing homes; (c) Own residence, the decedent's usual place of abode, but excludes communal living arrangements such as convents, monasteries, hostels or prisons; (d) Hospice, commonly standalone NHS or independent establishments; (e) Other places, covering psychiatric hospitals, other people's homes, communal living institutions as described above, workplaces, public spaces or roads. This grouping also applies to those declared dead on arrival at hospital, potentially relevant to some heart failure patients who succumb to sudden death. Where the PoD was unknown or unspecified, these data were incorporated in descriptive statistics but not considered further in multiple adjusted analyses.

Period of death as the independent variable of interest incorporated a binary indicator for the year of death pre- and post-enforcement of the MCA [0: 2001–2007; 1: 2008–2018]. Covariates included age at death, number of mentioned contributory causes, gender, marital status, socioeconomic position as measured by the Index of Multiple Deprivation, and categorisation of the location of decedents' usual residence as urban or rural based on the relevant postcode as archived on the ONS classification system [22, 23].

**Statistical analysis**

Categorical and continuous variables were described using count (percentages) and means (standard deviation [SD]) as appropriate. The number of patients who died from heart failure with comorbid dementia, and the proportion of hospital deaths among heart failure decedents with or without comorbid dementia were plotted to visually determine temporal trends. These were also assessed statistically using a two-tailed Cochran-Armitage trend test.

We used Poisson regression modelling to evaluate the independent association between enforcement of the MCA and PoD. Three model sets were constructed separately for heart failure patients who died with or without comorbid dementia: home (1) versus hospital (0); care home (1) versus hospital (0); hospice (1) versus hospital (0). All covariates were forced to stay in the models to control their effects. The prevalence ratio (PR) was derived from the respective model to quantify the magnitude of association.
All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA). To control for Type 1 error, we applied Bonferroni correction to the alpha level. A two-sided $p$ value of 0.008 (0.05 / 6) was considered statistically significant.

**Results**

**Study sample.**

Between 2001 and 2018, 120,068 people aged $\geq 65$ years whose deaths were registered as directly due to heart failure were identified, their data subsequently included in this analysis. Table 1 describes the characteristics of these heart failure decedents. Overall, 8199 (6.8% [confidence intervals (CI) 6.7 to 7.0]) of these registrations were documented with dementia (WD) as a contributory cause, this being classified as unspecified dementia in 78.2%, Alzheimer's disease in 13.5%, and as vascular dementia in 8.3%. No other dementia subtypes were denoted. For the periods 2001–2007 and 2008–2018, pre- and post-enforcement of the MCA, the number of heart failure decedents WD was 3427 (5.6%) and 4772 (8.0%) respectively. The proportion WD gradually increased on an annual basis, this trend being statistically significant ($Z = 18.87, p < 0.0001$) as shown on Fig. 1. There was no discernible artefactual change in the general rate of dementia mentioned as a contributory cause of death associated with the 2011 change in ONS coding practice. However, additional analysis, also incorporated in Fig. 1, shows a contemporaneous and statistically significant reduction ($p < 0.0001$) in the coding of 'unspecified dementia' with a comparable increase in coding for 'vascular dementia'.
The majority of these heart failure decedents were ≥ 85 years-old at time of death (62%). The mean age at death increased between the two study periods (2001–2007: 85.7 years [SD 7.4]; 2008–2018: 86.6 years [SD 7.5], the age at death being greater for those WD for both study periods at 87.1[SD 6.2] and 88.1 years [SD 6.0] respectively. A greater number of contributory comorbidities was more frequently mentioned for WD heart failure decedents. Most of those dying from heart failure were female, this proportionately greater at 67.1% for the WD group compared to 60.3% for those with no dementia (ND). Twenty-four per-cent of the WD cohort were married at the time of death as were 27% of the ND group, widowhood being more common in the former group at 65% against 60% for those without mention of dementia. Most lived and died in urban environments (81%) and deprivation quintiles were similar for both groups.

Also demonstrated on Table 1, it is noteworthy that the rate of all heart failure-related death registrations of people ≥ 65 years, whether or not they had comorbid dementia, declined by 52% across the observation period of this study. The mean annual reduction was 369 [SD 32], this being statistically significant ($p < 0.0001$).
Trends In Place Of Death

Over the period of implementation of the MCA, comparative outcomes in PoD for these heart failure decedents are shown in Fig. 2. For the period 2001–2007, hospital was the most common PoD for the ND group at 68.2%, 20.2% dying in a care home, and 10.7% dying at home. This changed a little for the latter period 2008–2018, reducing to 62.5% and 18.8% for hospital and care homes respectively, the proportion of home deaths increasing to 17.2%. In contrast, for heart failure decedents WD, there was a small increase in the proportion of hospital deaths, this rising from 47.6–50.4%. For this group, there was a reduction in care home deaths from 48.0–38.8%, with a modest rise in home deaths, 4.2–10.0%. Hospice as the PoD was rare for both clinical groups (≤ 0.5%) and declined over the study period. The time trend in hospital deaths is shown in Fig. 3. There was a statistically significant reduction in hospital deaths for ND decedents (p < 0.001). On the other hand, the marginal increase in hospital deaths for the WD cohort was not significant (p = 0.97).

Adjusted PRs following implementation of the MCA confirm increased PoD at home compared to hospital for ND patients, PR: 1.026 [CI: 1.024–1.029] (p < 0.0001), this trend not significant for those WD, PR: 1.001 [CI 0.988–1.015] (p = 0.83). Care home deaths reduced for both groups, PR: 0.996 [CI 0.993–0.998] (p < 0.0001), and PR: 0.959 [CI 0.949–0.969] (p < 0.0001) for ND and WD patients respectively. Starting from an already small base, adjusted PRs for hospice rather than hospital as PoD declined significantly for both ND and WD decedents being 0.979 [CI 0.978–0.981 (p < 0.0001), and 0.946 [CI 0.934–0.958] (p < 0.0001), respectively. A summary of the adjusted PRs for dying in a premise other than hospital following MCA enforcement is shown in Table 2. Fully detailed results for all three model sets are available in Supplementary Tables S-1, S-2 and S-3.

### Table 2

The adjusted prevalence ratios*(95% confidence intervals) of dying in a specific type of premise (compared to hospital death) after implementation of MCA in heart failure decedents with or without comorbid dementia, England 2001–2018.

|                      | With dementia                   | Without dementia                   |
|----------------------|---------------------------------|------------------------------------|
| Home                 | 1.001 (0.998 to 1.015)          | 0.83                               |
| Care home            | 0.959 (0.949 to 0.969)          | < 0.0001                           |
| Hospice              | 0.946 (0.934 to 0.958)          | < 0.0001                           |

*Greater than 1 indicates a higher chance of death in the corresponding type of premise.

### Discussion

In this first national study examining variation in the PoD for heart failure patients over the period of enactment and implementation of the MCA in England, our results suggest that the decision-making and advance care planning processes enshrined in this legislation had little material effect on the ultimate site of care provision determining PoD for those with cognitive impairment manifest as dementia. In the later years of this study period when the code of practice for this legislation was operational, trend data for heart failure decedents certified with comorbid dementia show a modest rise in hospital deaths with fewer care home deaths. Conversely, for this study phase, there was a small reduction in hospital deaths for those without dementia who were younger and with fewer comorbidities.

The reasons behind the apparent lack of impact of this legislation may be complex, but it has been proposed that the MCA is relatively poorly applied in clinical practice. While a variety of training models have been developed to disseminate information to health professionals on the five principles underpinning these regulations, recent reviews suggest poor understanding of when and how the provisions of the Act should be employed, with the need for clarity on the process of designating the role of surrogate decision-makers to properly ensure patients' best interests are maintained [24, 25, 26]. A lack of confidence of those working in acute care settings has been particularly highlighted, specifically citing decision-making with respect to hospital discharge [27]. This issue may be especially relevant to our study observations given that we have demonstrated that the majority of those dying with heart failure in England do so in hospital, similar to data from the United States (US) [28].

At variance with the trends evident in this study, previous work has suggested a decline in the frequency of hospital deaths for those with dementia in recent years, more people dying in care homes [29]. These findings were also based on ONS death certification data but included all individuals for whom dementia was mentioned as either the underlying or as a contributory cause of death. In contrast, the current study specifies heart failure as the underlying cause of death, differentiating the comparator groups by the presence or absence of dementia mentioned only as a contributory cause. While we have no information on any care transitions prior to the terminal phase for this study cohort, it is well established that the principal diagnosis is the main determinant of the site of clinical care [30], and community based primary care practitioners also appear to be relatively cognizant of patients’ preferences for place of care or PoD, particularly when dealing with non-cancer diagnoses [31]. Unless policies for comfort care are clearly outlined, should people with chronic heart failure living at home or in a nursing home suddenly deteriorate, professional staff may default to arranging emergency hospital admission.

The completeness of death certification in the UK is regarded as relatively robust with proportionately fewer 'garbage codes' than data from many other countries [32]. However, dementia as recorded on death certification likely underestimates the true prevalence, and it has been suggested that studies using death certification alone may fail to account for 16–18% of dementia cases [33]. A variety of factors may influence such documentation. Rates of inclusion of dementia are generally increased in those who die in institutions such as care homes compared to those dying at home, particularly if
dementia is at the severe end of the clinical spectrum and includes agitation [34]. While heart failure guidelines draw attention to cognitive impairment as a comorbidity, describing all grades of this by hospital-based clinicians is reportedly poor [14], and there are diverging views on whether dying in hospital positively or negatively affects the rate of recording of dementia at the time of death certification [34, 35]. Recent initiatives to heighten clinicians’ awareness of dementia may improve matters. In 2012, NHS England introduced a quality improvement scheme through the Commissioning for Quality and Innovation (CQUIN) payment framework [36]. Acute healthcare providers were incentivised with the assurance of increased remuneration if 90% of all patients aged ≥ 75 years and whose emergency hospital admission lasted > 72 hours were screened for dementia. Further financial gain was available if those patients whose initial assessment indicated dementia or was inconclusive were referred on for specialist review. While this dementia assessment and referral exercise was retired as a CQUIN indicator in April 2016, these conditions have been retained within the standard contract for English hospitals providing acute clinical services. It is possible that these administrative processes may have contributed in some measure to the increased mentions of dementia as certified for hospital decedents evident in the latter course of this study.

The relatively frequent concurrence of cognitive impairment and heart failure likely stems from various pathophysiologic features related to the latter condition combined with shared cardiovascular risk factors such as hypertension, hyperlipidaemia or dysglycaemia [7, 37, 38]. The haemodynamic and risk factor profiles for HFpEF and HFrEF clearly differ, but very few investigations have compared the spectrum of cognitive impairment across the range of ejection fraction phenotypes. There is a suggestion that affected domains of cognitive function may vary, but data is limited with inconsistent results [39, 40].

To date, there is no evidence that evidence-based guideline-directed medical therapy (GDMT) for heart failure drives neurocognitive dysfunction [41], and indeed it has been posited that centrally acting angiotensin-converting enzyme inhibitors (ACEIs) such as perindopril or captopril, which cross the blood-brain barrier, may slow progression of cognitive impairment in those with dementia [42]. Following the positive results of the PARADIGM-HF study demonstrating the benefits of sacubitril / valsartan, the first of a new class of drugs termed ARNIs (angiotensin receptor-neprilysin inhibitors) [43], this therapeutic option for HFpEF has been widely adopted. Neprilysin is a soluble metallopeptase which catalyses the degradation of natriuretic peptides (NP s), downregulation of this enzymatic activity likely increasing endogenous NP mediated natriuresis and vasodilation. However, such neprilysin inhibition might also interfere with clearance of amyloid-β protein, the vascular deposition of which results in cerebral amyloid angiopathy, a distinctive feature of Alzheimer’s disease. Dementia-related adverse events were not overrepresented through 4.3 years follow-up of the relevant PARADIGM-HF study cohort compared to similar populations [44]. Nonetheless, as required by the Food and Drug Administration in the US, this potential hazard is currently being evaluated in the PERSPECTIVE study (ClinicalTrials.gov ID NCT02884206). Due to report in 2022, this trial includes a battery of neurocognitive testing and sequential 18F-labelled flortebaetan positron emission tomography to assess any longitudinal changes in cerebral amyloid plaque burden. Importantly, recent evidence shows that the hearts of some patients with Alzheimer’s disease exhibit diastolic dysfunction and thickening of the interventricular septum. These features are characteristic of cardiac amyloidosis suggesting that in some individuals, amyloid-β protein may also accumulate in tissues other than the brain [45].

As inferred above, in recent years GDMT for those affected by heart failure has become increasingly sophisticated [46]. Beyond pharmacological therapy, this may include the implantation of electronic devices and durable mechanical circulatory support systems. While this complexity may be burdensome to some extent, there is also a beneficial trade off in that heart failure treatment has become more effective, which explains in part the temporal trend in declining heart failure death registrations noted over the observational period of this investigation. This is consistent with the reported 60% reduction in heart failure mortality based on analysis of death certification data between 1981 and 2010 in a study initially confined to the Oxford region but expanded from 1993 to include the entire English national population [47]. Over this 30-year study of the cause of death of all men and women aged ≥ 35 years, there were parallel reductions in mortality from acute myocardial infarction and other forms of ischaemic heart disease, such gains postulated as responses to public health measures improving modifiable cardiovascular risk factors, together with advances in clinical care. While this decline in cardiovascular mortality is to be celebrated, heart failure is an ambulatory care sensitive condition and remains the commonest cause of acute hospitalisation in those > 65 years [48]. Following an index heart failure admission in England, the 1-year mortality for patients discharged alive is 39.6% with a 30-day all-cause readmission rate of 19.8% [49]. Readmissions for heart failure tend to follow a tri-phasic pattern. This was apparent in a study of 8543 heart failure patients in Toronto monitored for 10 years following their index hospital admission, by which time 98.8% had died, the median survival after heart failure diagnosis being 1.75 years [50]. About 30% of all readmissions occurred within 2-months of initial hospital discharge, 50% during the 2-month period leading up to death, with 15–20% taking place in the intervening ‘plateau phase’ of the heart failure disease trajectories. A sentinel clustering of admissions in the terminal phase of heart failure has been well described [51]. It is uncertain if the presence of dementia as a comorbidity influences the readmission rate. Rao and colleagues followed 10,317 patients for 5 years subsequent to their first diagnosis with heart failure between April 2008 and March 2009 using the primary care based Clinical Practice Research Datalink combined with Hospital Episode Statistics and ONS death registration data [52]. Their analysis indicated that comorbid dementia was a factor significantly affecting emergency hospital readmissions in only 3 of 8 regions across England.

Comparable to the epidemiological trends for heart failure, the age-adjusted prevalence and incidence of dementia may also be declining in high income countries. The Medical Research Council Cognitive Function and Ageing Studies (CFAS 1 and II) of populations living in rural Cambridgeshire and the urban environments of Newcastle and Nottingham demonstrated a 24% reduction in the prevalence of dementia in those ≥ 65 years between 1999 and 2011 [53]. Consistent with our observations, the CFAS studies also suggested that women were more commonly affected, and while the prevalence of dementia in care home residents had increased from 56–70%, most people with dementia were still living at home. Similarly, dementia events have been continuously monitored in the US based Framingham Heart Study since 1975. Recent analyses of this community cohort living in Massachusetts, predominantly of white European ancestry, have implied a 20% stepwise decline in the incidence of dementia each decade over the last 30 years [54]. The
background to these cumulative decrements remains to be determined, but both the CFAS and Framingham study groups cited potential mechanisms in higher early educational attainment and attenuated vascular morbidity.

The Framingham Heart Study showed a non-significant reduction in Alzheimer's disease with a more overt decrease in vascular dementia. In Westernised societies, Alzheimer's is the most commonly encountered manifestation of dementia, but as an isolated pathophysiological process, this affects < 20% of those with heart failure. Rather, vascular dementia has been proposed as the likeliest associated variant, followed by mixed forms, then Alzheimer's and other specific dementias [39]. This is at odds with the distribution of dementia subtypes noted in this study where unspecified dementia was most frequently mentioned on death certificates and coded as the dominant category. A similar finding was described in a Danish study of 324,418 patients admitted with incident heart failure and tracked for 35 years against an age- and sex-matched population without heart failure selected from the Danish Civil Registration System [55]. Adelborg and colleagues found a clear association between all-cause dementia and heart failure. This was relatively weak for Alzheimer's disease, and while the vascular variant was represented, this was predominantly determined by the reported development of unspecified dementia. These authors proposed that some patients ostensibly exhibiting unspecified dementia may have been misclassified. However, in combining death certification data from sequential CFAS studies in England, all mentions of dementia as the underlying or a contributory cause of death showed a percentage distribution of subtypes of unspecified dementia, Alzheimer's disease and vascular dementia as 69.3%, 21.6% and 8.6% respectively [35]. These results are very similar to those noted in the current study and suggest that this proportional distribution of dementia variants is not specific to the heart failure population.

Advance care planning offers patients the potential to receive medical treatment consistent with their expressed preferences, values and goals of care against the possibility of subsequent loss of decision-making capacity. This may help prevent needless hospital admissions and better achieve consensus on appropriate ceilings of care, avoiding exposure of patients and families to the distressing harms which sometimes accompany futile treatment escalation and burdensome invasive interventions close to the end of life. It is notable that a recent audit of end-of-life care in hospitals in England demonstrated that 10% of heart failure patients were receiving mechanical ventilatory support within 24-hours of death [56].

Given the unpredictability intrinsic to the heart failure disease trajectory which challenges individual prognostication even in the late stages of this disease, and the associated multimorbidity including cognitive impairment, it might be expected that advance care planning would be central to the care of people with this condition. However, advance care planning is not routinely incorporated within heart failure care and tends to be limited to the possible withdrawal of some of the implanted devices described above, or sometimes offered as one component of the still uncommon provision of palliative care [57, 58]. A review and meta-analysis of 14 randomised controlled trials of advance care planning in heart failure, mostly US based and involving 2924 individuals across a range of care structures, showed this to moderately improve the primary outcome measure in patients' quality of life, together with similarly weighted favourable effects on secondary outcomes including communication about and satisfaction with end-of-life care [59].

Advance care planning for dementia was featured as a specific domain in the European Association of Palliative Care white paper on this condition [60], and the challenges taking this forward have been comprehensively reviewed [61, 62]. Emerging themes suggest that while there is some disparity in the readiness of older people to engage in advance care planning, and the means to take this forward may also vary across the spectrum of healthcare delivery, the use of these instruments may be effective in promoting shared decision-making between patients, informal carers and professionals [63]. However, it should be noted that, in the UK, an advance care plan is not legally binding but merely an advisory statement of preferences and wishes in relation to general care and medical therapy [64].

In contrast, the MCA and the associated code of practice offer legislative protection to promote patient empowerment and safeguard their autonomy. Prepared when mental capacity is intact, patients may formulate an advance decision such as one to refuse life-sustaining treatment or, if \( \geq \) 18 years, appoint a close person as a personal welfare lasting power of attorney (LPA) to undertake decisions on their behalf if agency is later lost. Thereafter, any clinical treatment protocol, where possible, should be in accordance with their previously documented choices and values, or these as expressed through their nominated personal welfare LPA. Importantly, we must emphasise that many people diagnosed with dementia can still make decisions about many aspects of their care, and loss of capacity should not be regarded as an all-or-none phenomenon based on that diagnostic label. Indeed, under the terms of the MCA, retention of capacity is assumed, and capacity is both decision and time specific. For the purposes of the Act, a two-stage capacity test is applicable. To qualify through Stage 1, the individual must exhibit a demonstrable functional impairment of the mind or brain. For Stage 2, capacity is deemed to be lost if they lack the ability to fulfil any of the following: (a) understand the information pertinent to the decision, (b) retain the information, (c) deliberate on that information as part of the decision-making process, and (d) communicate their decision by any means possible.

Dialogue between the patient, family and clinician is basic to shared decision-making. However, triangulation of information between this triad does not necessarily mean equitably weighted opinions, and at times patients' voices are marginalised, a dyadic interchange conducted between clinicians and family members. Such a discourse may be justified if the patient cannot physically contribute to meaningful shared decision-making, if capacity is deemed to be lost, legally binding instruments are not in place, and their preferences are unknown. Then, the opinion of the closest relative should be sought, their views respected, and used to inform a care plan constructed in the best interests of the patient. However, it should also be remembered that the involvement of relatives as decisional proxies may be emotionally demanding, particularly if there is tension between family members, or they are already distressed and experiencing anticipatory grief. Further, the assumption that there is always congruence between the opinions of family surrogate decision makers and those perceived of patients is flawed. Rather, these are often misaligned, with at best moderate concordance between dementia / carer dyads when assessed within a hospital setting [65]. Even if decisional consensus is achieved, the discharge of hospital inpatients home may be subject to practical limitations depending on the social context. The caregiver burdens associated with heart failure and dementia have been well characterised. Informal caregivers may be unwilling or unable to reframe or enhance their roles, and it should be noted that the cohabitees of people
living and dying with dementia tend to be of a similar advanced age [66]. As evident in this study, there may also be a gendering issue in that older women with heart failure and comorbid dementia are more likely to have outlived their male partners and be devoid of spousal support [67]. These intersectional aspects, constraining the social capital of those with heart failure and dementia close to the end of life, offer little prospect of mitigation [68, 69].

Strengths And Weaknesses

To our knowledge, this is the first national study to systematically examine the PoD of people dying of heart failure with dementia documented as a contributory cause of death. A major strength is that our work is based on comprehensive data collated from the gamut of clinical practice over an 18-year period, but we acknowledge that we are dependent on the clinicians responsible for these heart failure decedents having made the correct diagnoses and accurately completing later death certification, over which there is no means of independent adjudication. Irrespective of the PoD, we have no access to information on the underlying aetiologies of heart failure, or the proportional distribution of resultant ejection fraction variants. Similarly, it is not possible to ascertain the duration of heart failure or nature of any care provision prior to the terminal phase, and whether this fatal outcome related to incident acute heart failure, worsening of chronic heart failure, or heart failure-related sudden cardiac death. It has been suggested that decisions to include dementia on death certificates rely on medical staff regarding this as clinically significant [70]. This is considered more likely if dementia is relatively severe, reaffirming our judgement in using the certified mention of dementia as a contributory cause of death to represent a valid marker of significant cognitive dysfunction, and therefore relevant to the aegis of the MCA. With regard to generalisability, the results of this study are germane to similar clinical populations, models of care delivery, and legal constructs. While the legal status of the MCA 2005 is applicable to England and Wales, beyond this jurisdiction within the UK, this legislation is closely aligned to the Adults with Incapacity (Scotland) Act 2000, and the Mental Capacity Act (Northern Ireland) 2016. There is also some global resonance through Article 12 of the United Nations Convention on the Rights of Persons with Disabilities (CRPD) of 2006. Whilst the pertinence of specific aspects of the CRPD have been subject to legal argument [71], both this and the MCA have informed the development of mental capacity policies and legislation in Canada, Australia and New Zealand [72, 73].

Conclusions

In this paper, we have examined the impact of the MCA on the PoD of heart failure decedents aged ≥ 65 years whom we have shown to be increasingly affected by comorbid dementia, dying at home or usual place of residence customarily accepted as the preferred option. Our analyses of trends over the period of enactment and implementation of the code of practice relating to this legislation show little to suggest any significant influence on PoD for this relatively vulnerable clinical cohort. The background to this somewhat neutral outcome is multifaceted, administration of the Act clearly challenging for a prognostically ambiguous population subject to flux in the often-nuanced scenarios typical of real-life clinical practice, a milieu dominated by the treatment imperative. Further, even if the precepts of the MCA are correctly applied, this course of action may be ineffectual in isolation. Recent evidence suggests that achieving a good death at home requires patients and their informal carers to feel secure in that setting, effected by the provision of a 24/7 responsive palliative care service, staffed by those competent in symptom relief and with good communication skills [74]. Fulfilling the preferred PoD of those with heart failure and dementia might be better achieved by embedding application of the MCA within a system of anticipatory sympathetic clinical navigation across all care sectors, contingent upon effective upskilling of the relevant professionals, with good inter-agency and multidisciplinary collaboration to support and maintain appropriately configured community-based palliative care.

List Of Abbreviations

ACEI: Angiotensin converting enzyme inhibitor; ARNI: angiotensin receptor-neprilysin inhibitor; CFAS: Cognitive Function and Ageing Study; CQUIN: Commissioning for Quality and Innovation; EF: Ejection fraction; GDMT: Guideline directed medical therapy; HFimpEF: Heart Failure with improved Ejection Fraction; HFmrEF: Heart Failure with mildly reduced Ejection Fraction; HFpEF: Heart Failure with preserved Ejection Fraction; HFrEF: Heart Failure with reduced Ejection Fraction; ICD-10: International Classification of Diseases 10th Revision; ID: Identifier; LPA: Lasting Power of Attorney; Mental Capacity Act; NHS: National Health Service; ND: No dementia; NP: Natriuretic peptide; ONS: Office for National Statistics; PoD: Place of death; SD: Standard deviation; UK: United Kingdom; US: United States; WD: With dementia.

Declarations

Ethics and authorisation

In accordance with General Data Protection Regulations arising from the UK Data Protection Act (2018), as all patient level data was fully anonymised, no ethical approval was required. Wei Gao is accredited to analyse this data through the ONS Approved Researcher Scheme.

Availability of data and materials

Supplementary files S-1, S-2 and S-3 are available online.

Competing interests

The authors declare they have no competing interests.

Funding
Wei Gao and Irene J Higginson at King's College London are supported by the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed are those of the author[s] and not necessarily those of the NIHR or the Department of Health and Social Care. The funding bodies have no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors’ contributions

JMB: conception and design; organisation of the conduct of the study; interpretation of results; primary drafting and revision of the manuscript.

IJH and TAMcD: interpretation of the results; critical review and revision of the manuscript.

WG: conception and design; organisation of the conduct of the study; data acquisition and management; statistical analysis of the data; interpretation of results; drafting and revision of the manuscript. WG is guarantor of the data.

All authors approved the final version of the paper prior to submission.

Acknowledgements

The GUIDE_Care Services project (NIHR HS&DR: 14/19/22) and The GUIDE_Care project (NIHR HS&DR: 09/2000/58).

Pre-publication history

Presented in part at the 7th International Advance Care Planning Conference, Rotterdam, 2019.

ORCID IDs:

James M Beattie http://orcid.org/0000-0001-7370-3485

Irene J Higginson https://orcid.org/0000-0002-3687-1313

Theresa A McDonagh https://orcid.org/0000-0003-1305-9602

Wei Gao https://orcid.org/0000-0001-8298-3415

References

1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368–78. doi:10.1038/nrcardio.2016.25.

2. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespiolo AP, Allison M, Hemingway H, Clandel JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–80. doi:10.1016/S0140-6736(17)32520-5.

3. Taylor CJ, Ordoñez-Mena JM, Roallfie AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbis FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: Population based cohort study. BMJ. 2019;364:i223. doi:10.1136/bmj.i223.

4. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72. doi:10.1161/01.cir.0000039105.49749.6f.

5. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fizuat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021 Mar 1:S1071-9164(21)00050 – 6. doi:10.1016/j.cardfail.2021.01.022.

6. Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1,162,309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes. 2010;3(6):573–80. doi:10.1161/CIRCOUTCOMES.110.957571.

7. Witt LS, Rotter J, Stearns SC, Gottesman RF, Kucharska-Newton AM, Richey Sharrett A, Wruck LM, Bressler J, Sueta CA, Chang PP. Heart failure and cognitive impairment in the Atherosclerosis Risk in Communities (ARIC) Study. J Gen Intern Med. 2018;33(10):1721–8. doi:10.1007/s11606-018-4556-x.

8. Ampadu J, Morley JE. Heart failure and cognitive dysfunction. Int J Cardiol. 2015;178:12–23. doi:10.1016/j.ijcard.2014.10.087.

9. Cannon JA, Moffitt P, Perez-Moreno AC, Walters MR, Broomfield NM, McMurray JJV, Quinn TJ. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail. 2017;23(6):464–75. doi:10.1016/j.cardfail.2017.04.007.

10. Harvey PD. Domains of cognition and their assessment. Dialogues Clin Neurosci. 2019;21(3):227–37. doi:10.31887/DCNS.2019.21.3/pharvey.
11. Correale M, Altamura M, Camevale R, Tricarico L, Malerba S, Gallotta AM, Altamura C, Perrella M, Di Biase M, Bellomo A, Brunetti ND. Delirium in heart failure. Heart Fail Rev. 2020;25(5):713–23. doi:10.1007/s10741-019-09842-w.

12. Hammond CA, Blades NJ, Chaudhry SI, Dodson JA, Longstreth WT Jr, Heckbert SR, Psaty BM, Arnold AM, Dublin S, Sitlani CM, Gardin JM, Thielke SM, Nanna MG, Gottesman RF, Newman AB, Thacker EL. Long-term cognitive decline after newly diagnosed heart failure: longitudinal analysis in the CHS (Cardiovascular Health Study). Circ Heart Fail. 2018;11(3):e004476. doi:10.1161/CIRCHEARTFAILURE.117.004476.

13. Uchmanowicz I, Jankowska-Połańska B, Mazur G, Sivarajan Froelicher E. Cognitive deficits and self-care behaviors in elderly adults with heart failure. Clin Interv Aging. 2017;12:1565–72. doi:10.2147/CIA.S140309.

14. Dodson JA, Truong TT, Towle VR, Kerins G, Chaudhry SI. Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. Am J Med. 2013;126(2):120-6. doi: 10.1016/j.amjmed.2012.05.029. Erratum in: Am J Med. 2013;126(6):e25.

15. Huijts M, van Oostenbrugge RJ, Duits A, Burkard T, Muzzarelli S, Maeder MT, Schindler R, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF Investigators. Cognitive impairment in heart failure: results from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) randomized trial. Eur J Heart Fail. 2013;15(6):699–707. doi:10.1093/eurjhf/hft020.

16. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP; Krumholz HM, Mancini D, Riegel B, Spertus JA, American Heart Association; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology. Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125(15):1928–52. doi:10.1161/CIR.0b013e31824f2173.

17. Her Majesty’s Government (UK). Mental Capacity Act 2005. London: The Stationary Office Limited; 2005.

18. Gomes B, Calanzani N, Higginson IJ. Local preferences and place of death in regions within England 2010. Cicely Saunders International, 2011. https://www.kcl.ac.uk/cicelysaunders/attachments/keyreport-Local-preferences-and-place-of-death-in-regions-within-England.pdf Accessed 15 Feb 2021.

19. Mental Capacity Act. 2005. Code of Practice. London. 2007. The Stationary Office Limited. https://www.gov.uk/government/publications/mental-capacity-act-code-of-practice Accessed 5 Jan 2021.

20. Dying with Dementia. National Dementia Intelligence Network and National End of Life Care Intelligence Network briefing. Public Health England. (2016). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/733064/Dying_with_dementia_briefing.pdf Accessed 18 Dec 2020.

21. Public Health England. Classification of Place of Death. A technical bulletin from the National End of Life Intelligence Network. March 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/831853/Classification_Place_Death_report.pdf Accessed 12 Nov 2020.

22. Department for Communities and Local Government. London. 2015. The English Indices of Multiple Deprivation 2015. https:// Accessed 20 Dec 2020.

23. Office for National Statistics. Rural / Urban classifications: The classification systems used to produce a rural / urban view from government statistics. 2011. https:// Accessed 7 Dec 2020.

24. Hinsliff-Smith K, Feakes R, Whitworth G, Seymour J, Moghaddam N, Dening T, Cox K. What do we know about the application of the Mental Capacity Act (2005) in healthcare practice regarding decision-making for frail and older people? A systematic literature review. Health Soc Care Community. 2017;25(2):295–308. doi:10.1111/hsc.12310.

25. Jenkins C, Webster N, Smythe A, Cowdell F. What is the nature of Mental Capacity Act training and how do health and social care practitioners change their practice post-training? A narrative review. J Clin Nurs. 2020;29(13–14):2093–106. doi:10.1111/jocn.15256.

26. Wade DT, Kitzinger C. Making healthcare decisions in a person's best interests when they lack capacity: clinical guidance based on a review of evidence. Clin Rehabil. 2019;33(10):1571–85. doi:10.1177/0269215519852987.

27. Poole M, Bond J, Emmett C, Greener H, Louw SJ, Robinson L, Hughes JC. Going home? An ethnographic study of assessment of capacity and best interests in people with dementia being discharged from hospital. BMC Geriatr. 2014;14:56. doi:10.1186/1471-2318-14-56.

28. Chuzi S, Molsberry R, Ogunseitan A, Warraich HJ, Wilcox JE, Grady KL, Yancy CW, Khan SS. Trends in place of death for cardiovascular mortality related to heart failure in the United States from 2003 to 2017. Circ Heart Fail. 2020;13(2):e006587. doi:10.1161/CIRCHEARTFAILURE.119.006587.

29. Sleeman KE, Ho YK, Verme J, Gao W, Higginson IJ. GUIDE_Care project. Reversal of English trend towards hospital death in dementia: a population-based study of place of death and associated individual and regional factors, 2001–2010. BMC Neurol. 2014;14:59. doi:10.1186/1471-2377-14-59.

30. Murtagh FEM, Bausewein C, Petkova H, Sleeman KE, Dodd RH, Johnston B, Murray S, Banerjee S, Shipman C, Hansford P, Wakefield D, Gomes B, Higginson IJ. Understanding place of death for patients with non-malignant conditions: a systematic literature review. Final report. NIHR Service Delivery and Organisation programme; 2012.

31. Abashti E, Onwuteaka-Philipsen B, Donker G, Echteld M, Van den Block L, Deliens L. General practitioner awareness of preferred place of death and correlates of dying in a preferred place: a nationwide mortality follow-back study in the Netherlands. J Pain Symptom Manage. 2009;38(4):568–77. doi:10.1016/j.jpainsymman.2008.12.007.

32. Iburg KM, Mikkelsen L, Adair T, Lopez AD. Are cause of death data fit for purpose? Evidence from 20 countries at different levels of socio-economic development. PLoS One. 2020;15(8):e0237539. doi:10.1371/journal.pone.0237539. https://journals.plos.org/plosone/article?
33. Russ TC, Gatz M, Pedersen NL, Hannah J, Wyper G,atty GD, Deary IJ, Starr JM. Geographical variation in dementia: examining the role of environmental factors in Sweden and Scotland. Epidemiology. 2015;26(2):263–70. doi:10.1097/EDE.0000000000000230.

34. Perera G, Stewart R, Higginson IJ, Sleeman KE. Reporting of clinically diagnosed dementia on death certificates: retrospective cohort study. Age Ageing. 2016;45(5):668–73. doi:10.1093/ageing/afw077.

35. Gao L, Calloway R, Zhao E, Brayne C, Matthews FE, Medical Research Council Cognitive Function and Ageing Collaboration. Accuracy of death certification of dementia in population-based samples of older people: analysis over time. Age Ageing. 2018;47(4):589–94. doi:10.1093/ageing/afy068.

36. Harrison JR. Improving inpatient care for older adults: Implementing dementia Commissioning for Quality and Innovation (CQUIN). BMJ Quality Improvement Reports 2017;6;u212202.w4875. doi: 10.1136/bmjquality.u212202.w4875. https://bmjopenquality.bmj.com/content/6/1/u212202.w4875.

37. van der Velpen IF, Feleus S, Bertens AS, Sabayan B. Hemodynamic and serum cardiac markers and risk of cognitive impairment and dementia. Alzheimers Dement. 2017;13(4):441–53. doi:10.1016/j.jalz.2016.09.004.

38. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day JD. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm. 2010;7(4):433–7. doi:10.1016/j.hrthm.2009.12.004.

39. Cermakova P, Lund LH, Fereinestehnejad SM, Johnell K, Winblad B, Dahlström U, Erskilder M, Religa D. Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. Eur J Heart Fail. 2015;17(6):612–9. doi:10.1002/ejhf.222.

40. Athilingam P, D’Aoust RF, Miller L, Chen L. Cognitive profile in persons with systolic and diastolic heart failure. Congest Heart Fail. 2013;19(1):44–50. doi:10.1111/chf.12001.

41. Bratzke LC, Moser DK, Pellet MM, Paul SM, Nesbitt TS, Cooper LS, Dracup KA. Evidence-based heart failure medications and cognition. J Cardiovasc Nurs. 2016;31(1):62–8. doi:10.1097/JCN.0000000000000216.

42. Gao Y, O’Caoinch R, Healy L, Kerins DM, Eustace J, Guyatt G, Sammon D, Molloy DW. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. 2013;3(7):e002881. doi:10.1136/bmjopen-2013-002881. https://bmjopen.bmj.com/content/3/7/e002881.

43. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077.

44. Cannon JA, Shen L, Jhund PS, Kristensen SL, Keber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ. PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(1):129–37. doi:10.1002/ejhf.687.

45. Sanna GD, Nusdeo G, Piras MR, Forteleoni A, Murr MR, Saba PS, Dore S, Sotgiu G, Parodi G, Ganau A. Cardiac abnormalities in Alzheimer Disease: clinical relevance beyond pathophysiological rationale and instrumental findings? JACC Heart Fail. 2019;7(2):121–8. doi:10.1016/j.jchf.2018.10.022.

46. Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2021 Update to the 2017 ACC Expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021:S0735-1097(20)37867-0. doi:10.1016/j.jacc.2020.11.022.

47. Rahimi K, Duncan M, Pitcher A, Emdin CA, Goldacre MJ. Mortality from heart failure, acute myocardial infarction and other ischaemic heart disease in England and Oxford: a trend study of multiple-cause-coded death certificate. J Epidemiol Community Health. 2015;69(10):1000–5.

48. Rahimi K, Duncan M, Pitcher A, Emdin CA, Goldacre MJ. Mortality from heart failure, acute myocardial infarction and other ischaemic heart disease in England and Oxford: examining the role of environmental factors in Sweden and Scotland. Epidemiology. 2015;26(2):263–70. doi:10.1097/EDE.0000000000000230.

49. Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy D, Lee DS. Lifetime analysis of hospital admissions and survival of patients newly admitted with heart failure. Circ Heart Fail. 2012;5(4):414–21. doi:10.1161/CIRCHEARTFAILURE.111.964791.

50. Udelson JE, Stevenson LW. The future of heart failure diagnosis, therapy, and management. Circulation. 2016;133(25):2671–86. doi:10.1161/CIRCULATIONAHA.116.023518.

51. Rao A, Kim D, Dazi A, Majeed A, Aylin P, Bottle A. Regional variations in trajectories of long-term readmission rates among patients in England with heart failure. BMC Cardiovasc Disord. 2019;19(1):86. doi:10.1186/s12872-019-1057-8.

52. Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, Brayne C, Medical Research Council Cognitive Function and Ageing Collaboration. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013:382(9902):1405–12. doi:10.1016/S0140-6736(13)61570-6.

53. Satizabal CL, Beiser AS, Chouraki V, Chenê G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham heart study. N Engl J Med. 2016;374(6):523–32. doi:10.1056/NEJMoai504327.
55. Adelborg K, Horváth-Puhó E, Ording A, Pedersen L, Sørensen HT, Henderson VW. Heart failure and risk of dementia: a Danish nationwide population-based cohort study. Eur J Heart Fail. 2017;19(2):253–60. doi:10.1002/ejhf.631.

56. Royal College of Physicians. End of Life Care Audit – Dying in Hospital. London: Royal College of Physicians. 2016. https://www.rcplondon.ac.uk/projects/outputs/end-life-care-audit-dying-hospital-national-report-england-2016 Accessed 17 Feb 2021.

57. Butler J, Binney Z, Kalogeropoulos A, Owen M, Clevenger C, Gunter D, Georgiopoulou V, Quest T. Advance directives among hospitalized patients with heart failure. JACC Heart Fail. 2015;3(2):112–21. doi:10.1016/j.jchf.2014.07.016.

58. Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, Adams PA, Speck A, Johnson KS, Krishnamoorthi A, Yang H, Anstrom KJ, Dodson GC, Taylor DH Jr, Kirchner JL, Mark DB, O'Connor CM, Tulsry JA. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017;70(3):331–41. doi:10.1016/j.jacc.2017.05.030.

59. Schichtel M, Wee B, Perera R, Onakpoya I. The effect of advance care planning on heart failure: a systematic review and meta-analysis. J Gen Intern Med. 2020;35(3):874–84. doi:10.1007/s11606-019-05482-w.

60. van der Steen JT, Radbruch L, Hertogh CM, de Boer ME, Hughes JC, Larkin F, Francke AL, Jünger S, Gove D, Firth P, Koopmans RT, Volcier L, European Association for Palliative Care (EAPC). White paper defining optimal palliative care in older people with dementia: a Delphi study and recommendations from the European Association for Palliative Care. Palliat Med. 2014;28(3):197–209. doi:10.1177/0269216313493685.

61. Harrison Dening K, Sampson EL, De Vries K. Advance care planning in dementia: recommendations for healthcare professionals. Palliat Care. 2019;12:1178224219826579. doi:10.1177/1178224219826579.

62. Jones K, Birchley G, Huxtable R, Clare L, Walter T, Dixon J. End of life care: A scoping review of experiences of advance care planning for people with dementia. Dementia (London). 2019;18(3):825–45. doi:10.1177/1471301216676121.

63. Fried TR, Redding CA, Robbins ML, Paiva A, O'Leary JR, Iannone L. Stages of change for the component behaviors of advance care planning. J Am Geriatr Soc. 2010;58(12):2329–36. doi:10.1111/j.1532-5415.2010.03184.x.

64. Birchley G, Jones K, Huxtable R, Dixon J, Kitzinger J, Clare L. Dying well with reduced agency: a scoping review and thematic synthesis of the decision-making process in dementia, traumatic brain injury and frailty. BMC Med Ethics. 2016;17(1):46. doi:10.1186/s12910-016-0129-x.

65. Miller LM, Whitlatch CJ, Lee CS, Lyons KS. Incongruent perceptions of the care values of hospitalized persons with dementia: a pilot study of patient-family caregiver dyads. Aging Ment Health. 2016;58(12):2329–36. doi:10.1186/s12910-016-0129-x.

66. Sampson EL, Lodwick R, Rait G, Candy B, Low J, Petersen I. Living with an older person dying from cancer, lung disease, or dementia: health outcomes from a general practice cohort study. J Pain Symptom Manage. 2016;51(5):839–48. doi:10.1016/j.jpainsymman.2015.12.319.

67. Gott M, Morgan T, Williams L. Gender and palliative care: a call to arms. Palliat Care Soc Pract. 2020;14:2632352420957997. doi:10.1177/2632352420957997.

68. Lewis JM, DiGiacomo M, Luckett T, Davidson PM, Currow DC. A social capital framework for palliative care: supporting health and well-being for people with life-limiting illness and their carers through social relations and networks. J Pain Symptom Manage. 2013;45(1):92–103. doi:10.1016/j.jpainsymman.2011.12.283.

69. Sawyer JM, Sallnow L, Kupeli N, Stone P, Sampson EL. Social networks, social capital and end-of-life care for people with dementia: a realist review. BMJ Open. 2019;9(9):e030703. doi:10.1136/bmjopen-2019-030703.

70. Sibbett RA, Russ TC, Deary IJ, Starr JM. Dementia ascertainment using existing data in UK longitudinal and cohort studies: a systematic review of methodology. BMC Psychiatry. 2017;17(1):239. doi:10.1186/s12888-017-1401-4.

71. Bartlett P. At the interface between paradigms: English mental capacity law and the CRPD. Front Psychiatry. 2020;11:570735. doi:10.3389/fpsyt.2020.570735.

72. Davidson G, Brophy L, Campbell J, Farrell SJ, Gooding P, O'Brien AM. An international comparison of legal frameworks for supported and substitute decision-making in mental health services. Int J Law Psychiatry. 2016;44:30–40. doi:10.1016/j.ijlp.2015.08.029.

73. Douglass A. Mental Capacity: Updating New Zealand's Law and Practice (Report for the New Zealand Law Foundation, Dunedin, July 2016) http://www.lawfoundation.org.nz/ Accessed 18 May 2021.

74. Sarmento VP, Gysels M, Higginson IJ, Gomes B. Home palliative care works: but how? A meta-ethnography of the experiences of patients and family caregivers. BMJ Support Palliat Care. 2017;7:390–403. doi:10.1136/bmjspcare-2016-001141.
Figure 1
Percentages of heart failure decedents (n=120068) with comorbid dementia (n=8199) by year of death, England, 2001-2018.
Figure 2

Comparative outcomes (%) in place of death for heart failure decedents with and without comorbid dementia pre- (2001-2007) and post- (2008 – 2018) implementation of the Mental Capacity Act (MCA).

Figure 3
The time trend of hospital deaths among patients who died from heart failure with or without comorbid dementia, England 2001-2018.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- FinalSupplements.docx